



# Focal cryotherapy for prostate cancer: a contemporary literature review

Srinath Kotamarti, Thomas J. Polascik

Division of Urologic Surgery, Duke Cancer Institute, Durham, NC, USA

*Contributions:* (I) Conception and design: Both authors; (II) Administrative support: Both authors; (III) Provision of study materials or patients: Both authors; (IV) Collection and assembly of data: S Kotamarti; (V) Data analysis and interpretation: Both authors; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.

*Correspondence to:* Thomas J. Polascik, MD, FACS. Division of Urology, Duke Cancer Institute, Durham, NC 27710, USA.

Email: Thomas.polascik@duke.edu.

**Objective:** To perform a comprehensive review of the contemporary literature regarding both functional and oncologic outcomes after primary focal cryotherapy for prostate cancer (PCa), providing these results as a foundation for discussing recent developments in the realm of focal therapy.

**Background:** Traditional treatments for PCa are often associated with debilitating functional side effects for patients. Due to advances in imaging and biopsy strategies, focal ablative therapies recently have garnered much interest and offer an alternative primary treatment for PCa patients with localized disease. Focal cryoablation utilizes heat extraction from tissues to generate an iceball and cause tissue destruction while sparing uninvolved prostatic regions. Optimized patient selection and postoperative management continue to be areas of interest and study as the field continues to develop.

**Methods:** A search was performed of the PubMed and Embase databases to identify articles pertaining to primary focal PCa cryoablation since our group's last comprehensive review in 2016.

**Conclusions:** Primary focal cryoablation for PCa offers optimized functional outcomes and a favorable adverse event profile. True evaluation of oncologic outcomes is hampered by lack of long-term follow-up and highly variable clinical endpoints across these studies. Nonetheless, outcomes appear adequate in the short-to medium-term time frame. Utilization of focal cryoablation is expected to grow with continued refinement of patient selection and management options in cases of treatment failure.

**Keywords:** Prostate cancer (PCa); focal therapy; cryoablation; image-targeted therapy; outcomes

Submitted Sep 23, 2021. Accepted for publication Dec 23, 2021. Published online Jan 10, 2022.

doi: 10.21037/atm-21-5033


View this article at: <https://dx.doi.org/10.21037/atm-21-5033>

## Introduction

The second most common cancer in men, prostate cancer (PCa) is confined to the prostate gland as localized disease in 90% of men at diagnosis (1). Such patients requiring treatment have traditionally been offered either extirpative resection or whole gland radiotherapy, with either option offering adequate oncologic outcome (2,3). Unfortunately, such treatments are not uncommonly associated with unintended damage to surrounding structures such as the urinary sphincter, pelvic floor, and neurovascular bundles that can negatively impact a man's urinary and sexual

function (4,5). Increased patient intolerance of these side effects has been fueled in recent years from heightened awareness related to unlimited internet-accessible information (3). To decrease patient burden from treatment, there has been an impetus to develop alternative treatment approaches for PCa with an emphasis on maximizing genitourinary functional outcomes while not compromising the oncologic outcome.

In recent years, investigations into partial prostate ablation gained attention after subtotal treatment demonstrated effectiveness in several other cancers,



**Figure 1** Review search protocol.

including renal, breast and lung (6-8). Improvements in imaging and diagnostic methods such as multiparametric magnetic resonance imaging (mpMRI) and targeted tissue biopsy have supported the implementation of focal treatment for appropriate candidates with clinically localized PCa (9). Studies including the PIVOT trial have also demonstrated the option to defer active treatment for lower risk disease (10). Thus, identification of a specific focus of clinically significant disease allows for targeted therapy while sparing uninvolved tissues, minimizing deleterious collateral effects to structures associated with sexual and urinary function (11). Even if untreated prostatic tissue harbors low risk disease, it may be surveilled and subsequently treated as necessary (10).

A thermal ablative technique, cryoablation causes destructive effects to intended target tissue via extraction of heat (12). It has a long history as an accepted ablative whole gland therapy for PCa and was first introduced as an alternative management for those patients unsuitable for primary means of treatment (12). Cryoablation has also undergone continued technologic development with improvement of utilized devices and associated imaging (11). Implemented as an option for focal PCa treatment, cryotherapy continues to be studied with several aspects including ideal patient selection and optimal postoperative management still being defined (11). In 2016, our group provided the last comprehensive dedicated review for PCa

focal cryoablation, to our knowledge (11). We sought to review the contemporary literature since then for primary focal cryotherapy and provide context for these studies as the field continues to evolve. We present the following article in accordance with the Narrative Review reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5033/rc>).

## Methods

Our group previously published a review on localized PCa primary focal cryoablation in 2016, commenting on associated oncologic and functional outcomes (11). To build on the prior findings and provide a comprehensive review of more recent distinct studies, a systematic search of the PubMed and Embase databases was performed to identify reports of primary focal cryotherapy for PCa since the time of the prior review. Combinations of the following terms were utilized to perform the search: ‘cryotherapy’ OR ‘cryoablation’ OR ‘cryosurgery’ OR ‘partial ablation’ OR ‘image guided therapy’ AND ‘focal’ AND ‘prostate’. *Figure 1* details the review protocol performed for this study. Studies including either oncologic or functional outcomes or both were selected. Full text versions of studies were favored over abstracts. Studies with multiple comparative arms including focal cryoablation were acceptable as long as focal cryotherapy-specific results were able to be isolated. Studies discussing salvage focal cryotherapy were excluded. In the event of multiple reports from a particular cohort, the latest study was selected. However, if a group presented separate articles for oncologic and functional outcomes, both articles were included. Articles presenting focal cryotherapy as a single arm of a multi-arm study were included if outcomes specific to cryoablation were available.

## Results

The search protocol yielded 13 studies that were identified for inclusion after thorough assessment (*Figure 1*) (13-25). Eight studies were single center series, while three were multicenter cohorts and two were derived from the Cryo On-Line Data (COLD) multi-center registry. All included reports discussed primary focal prostate cryoablation.

### Inclusion criteria

*Table 1* includes basic inclusion criteria for the presented studies. The most recent included study’s publication date

**Table 1** Inclusion, selection, ablation type, and follow-up protocols

Study	Year	N	Criteria for inclusion	Diagnostic workup	Ablation type	Follow-up protocol
Kongnyuy <i>et al.</i> (13)	2017	163	Unilateral localized disease	Not recorded	Hemiablation	PSA checks: year 1—every 3 months. Then every 6 months
Tay <i>et al.</i> (14)	2017	166	GGG2, PSA >10–20, clinical stage T2b	Not recorded	“Partial”	Not recorded
Elshafei <i>et al.</i> (15)	2018	829	Localized disease	Not recorded	“Partial”	Not recorded
Kongnyuy <i>et al.</i> (16)	2018	104	Unilateral positive cores < GGG4. Occasional patients with unilateral > GGG3	Not recorded	Hemiablation	Every 3 months for a year, every 6 months thereafter for PSA and digital rectal exams
Werneburg <i>et al.</i> (17)	2018	88	PSA <10, unilateral disease, lack of MRI ECE	Not recorded	Hemiablation	PSA at 3-month intervals
Inoue <i>et al.</i> (18)	2019	5	MRI visible, targeted biopsy proven GGG3 localized disease	3-D mapping biopsy	Targeted	Not recorded
Bakavicius <i>et al.</i> (19)	2019	126	Localized disease	Systematic and targeted transperineal biopsies	Treatment of specific area of the prostate with a 10 mm safety margin	Not recorded
Shah <i>et al.</i> (20)	2019	122	GGG2 or 3, or high volume GGG1	Transperineal mapping or systematic + targeted biopsy or systematic biopsy with concordant MRI	Unilateral anterior, bilateral anterior, bilateral posterior	PSA testing 3 to 6 monthly in first year and 6 months thereafter. MRI at 12 months. Biopsy performed when recurrence was suspected
Oishi <i>et al.</i> (21)	2019	160	Unilateral or bilateral with low volume contralateral disease	Systematic ± targeted biopsy (when MRI was available)	Hemiablation	PSA, digital rectal exams, and imaging (transrectal ultrasound vs. MRI) every 3 months in year 1, every 6 months years 2 to 5, annually thereafter. Biopsy at 12 months
Wysock <i>et al.</i> (22)	2021	83	MRI lesion concordant with biopsy < GGG4, no gross ECE	Systematic and targeted biopsy or systematic biopsy if concordance between with MRI	Does not differentiate beyond “partial”	PSA testing at 3 and 6 months and then every 6 months. Reflex MRI and prostate biopsy at 6, 24, and 60 months
Gregg <i>et al.</i> (23)	2021	23	PSA ≤10, <50% cores positive, ≤50% tumor core length, GGG1–2	Confirmatory systematic biopsy using robotic assistance	Anterior hockey stick	3, 6, 12, 18, 24 and 36 months time points (exam, PSA, quality of life measures)
Tan <i>et al.</i> (24)	2021	71	Individualized partial gland ablation	Fusion biopsy or 3-D template mapping biopsy	Targeted, hemiablation, subtotal (hockey stick)	Every 6 months for 5 years (PSA and exam). MRI: 3–6, 12–24 months, and at 5 years. Biopsy if PSA >0.5 ng/mL
Marra <i>et al.</i> (25)	2021	121	Low/intermediate risk	Systematic or saturation or MRI targeted biopsy	Lesional, quadrant, hemiablation	PSA every 3 months for the 1st year, then every 6 months. MRI: 3–12 months. Biopsy at 1 year

PSA, prostate specific antigen; GGG, Gleason grade group; MRI, magnetic resonance imaging; ECE, extracapsular extension; 3-D, 3-dimensional.

was 4/2021. Inclusion criteria amongst the studies varied, with 4 of 13 studies simply incorporating localized or unilateral localized disease, while the nine other studies mentioned parameters including variations of prostate specific antigen (PSA), mpMRI findings, or biopsy Gleason grade group (GGG). Eleven studies analyzed oncologic outcomes, seven studies analyzed functional outcomes, and six presented results for both. Ten studies were retrospective in nature, while three were prospective. Overall, eight studies (61.5%) explained their pre-intervention diagnostic workup, with most reports utilizing either 3-dimensional (3-D) mapping biopsy or mpMRI fusion-targeted biopsy with systematic core sampling. Regarding the prospective studies, Inoue *et al.* (18) included patients with biopsy proven localized GGG3 PCa from MR fusion targeted biopsy using 3-D mapping technology; clinically significant PCa (csPCa) was not allowed to be detected on systematic biopsy. Wysock *et al.* (22) included only those patients with biopsy proven GGG <4 using the Artemis® (Eigen, Grass Valley, CA, USA) biopsy platform, without extraprostatic extension identified on mpMRI, and no GGG1 core length >5 mm on the contralateral side of the prostate. In the last prospective study, Gregg *et al.* (23) included patients with <50% of cores positive from a particular side of the gland, PSA ≤10 ng/mL, no greater than 50% core length, only GGG1 or 2, and contralateral GGG1 ≤2 mm if present. Because mpMRI was not standard practice for their group at the time of the study, entry biopsies were performed in a systematic fashion only followed by a confirmatory biopsy in eligible patients with either the TargetScan Transrectal Ultrasound System (Envisioneering Medical Technologies, St. Louis, MO, USA) or the Artemis System (Eigen) (23) (Table 1).

### **Demographics and basic clinical parameters**

The total number of patients included from all studies was 2,062, comprised of 995 patients from the COLD registry, 111 from prospective studies, and 956 from retrospective articles. The smallest cohort was that of Inoue *et al.* (18) with 5 patients and the largest was reported from the COLD registry from Elshafei *et al.* (15) (829 patients). Mean/median age and PSA from the cohorts ranged from 64 to 72 years and 3.9 to 10.8 ng/mL, respectively (Table 2). Patient stratification according to D'Amico risk category when available or GGG are presented in Table 2. Seven (53.8%) studies included high risk patients with a range of 1.4% to 28.7% ≥ GGG4 across the cohorts. Of 8 studies

that presented D'Amico risk stratification, five cohorts were predominantly intermediate risk while three featured mostly low risk patients.

### **Focal technique**

Cryoablation pattern of ablation was described as either hemiablation-only (4 reports), targeted-only (1), anterior hockey stick-only (1), or a mix of these approaches (4). Three series did not have the approach described, including the two reports presenting data from the COLD registry, which does not offer this information (Table 1).

In all studies, cryoneedles were placed and the procedure was monitored under real-time transrectal ultrasound (US). Every study described the utilization of at least two freeze-thaw cycles with intralesional temperature targeted to a minimum of -40 °C. For those articles suggesting more than two cycles, Wysock *et al.* (22) stated utilization of a minimum of two freeze-thaw cycles, and Inoue *et al.* (18) described using two to three cycles with a median target intralesional temperature of -51 °C. A total of 8 of 13 (61.5%) articles mentioned using thermocouples and 7 mentioned utilizing a urethral warmer catheter (53.8%). Notably, the COLD registry does not report details of the focal therapy technique employed.

### **Follow-up protocols**

Follow-up protocols were described in nine (69.2%) of the included studies. All nine articles reported follow-up every 3–6 months for basic outcome measures i.e., physical exam including a digital rectal exam, PSA, and quality of life assessment. Five studies (38.5%) included mpMRI as part of the post-operative protocol starting at 3–12 months post-procedure (20–22,24,25). Four studies utilized mandatory biopsy as part of the protocol (21–23,25), with other cohorts performing a “for cause” biopsy if suspicion for recurrence arose. Biopsy technique, when mentioned, included sampling of both the treated and non-treated prostate (Table 1).

### **Oncologic outcomes**

Eleven (84.6%) studies specifically analyzed oncologic outcomes, which are presented in Table 3. Mean/median follow-up ranged from 6 to 85 months. Rate of post-procedural PSA decline was reported by two studies, with both Inoue *et al.* and Wysock *et al.* (18,22) demonstrating

Table 2 Preoperative clinical characteristics

Study	Year	N	Age in years	PSA in ng/mL	Patient risk stratification (D'Amico criteria when available, otherwise GGG)
Kongnyuy <i>et al.</i> (13)	2017	163	Median 72 (IQR, 67–78)	Mean 6.2 (IQR, 4.3–7.8)	Low—85 (52%) Intermediate—67 (41%) High—11 (7%)
Tay <i>et al.</i> (14)	2017	166	Mean 68.8 (SD: 8.0)	Mean 7.6 (SD: 4.0)	Intermediate (included 34.9% GGG1)—166 (100%)
Elshafei <i>et al.</i> (15)	2018	829	Median 68 (IQR, 63–74)	Median 5.6 (IQR, 4.4–7.5)	Low—504 (60.9%) Intermediate—246 (29.7%) High—76 (9.2%)
Kongnyuy <i>et al.</i> (16)	2018	104	Mean 66 (range, 48–82)	Mean 6.5 (IQR, 4.7–8.1)	Low—41 (39.4%) Intermediate—53 (51%) High—8 (7.6%)
Werneburg <i>et al.</i> (17)	2018	88	Mean 68 (range not provided)	Not specified	GGG1—37 (42.1%), GGG2—39 (44.3%), GGG3—12 (13.6%)
Inoue <i>et al.</i> (18)	2019	5	Mean 68 (range, 54–81)	Median 6.63 (range, 4.18–8.39)	Intermediate—5 (100%)
Bakavicius <i>et al.</i> (19)	2019	126	Mean 67 (SD: 6.9)	Mean 7.3 (SD: 3.1)	GGG1—94 (74.6%), GGG2—31 (24.6%), GGG3—1 (0.8%)
Shah <i>et al.</i> (20)	2019	122	Median 68.7 (IQR, 65–74)	Median 10.8 (IQR, 7.8–15.6)	Intermediate—87 (71.3%) High—35 (28.7%)
Oishi <i>et al.</i> (21)	2019	160	Median 67 (IQR, 60–74)	Mean 6.3 (IQR, 4.2–9.0)	Low—29 (18%) Intermediate—106 (66%) High—25 (16%)
Wysock <i>et al.</i> (22)	2021	83	Mean 64 (range, 59–70)	Median 6.18 (range, 4.6–7.8)	GGG1—9 (11%), GGG2—51 (61%), GGG3—23 (28%)
Gregg <i>et al.</i> (23)	2021	23	Median 64 (range, 56–68)	Mean 3.9 (SD: 2.1)	GGG1—18 (78.3%), GGG2—5 (22.7%)
Tan <i>et al.</i> (24)	2021	71	Median 66.7 (IQR, 60–72)	Median 6.55 (IQR, 4.80–8.85)	GGG1—30 (42.3%), GGG2—33 (46.5%), GGG3—5 (7%), GGG4—2 (2.8%), GGG5—1 (1.4%)
Marra <i>et al.</i> (25)	2021	121	Median 66 (IQR, 62–71)	Median 6.42 (IQR, 5.03–8.08)	Low—79 (65.3%) Intermediate—40 (33.1%) High—2 (1.6%)

PSA, prostate specific antigen; GGG, Gleason grade group; IQR, interquartile range; SD, standard deviation.

median decline in PSA by approximately 71% at 6 months. The same studies commented on mpMRI findings postoperatively, with Inoue *et al.* (18) describing zero persistent lesions that were treated on mpMRI at 6–12 months, while Wysock *et al.* (22) demonstrated mpMRI to have a poor area under the curve (AUC) of 0.554 to

predict subsequent biopsy in-field persistence. Biochemical failure was reported in five studies, with three using the Phoenix criteria, one using both Phoenix and Astro criteria, and one using both Phoenix and Stuttgart criteria. Utilizing Phoenix criteria, one study reported a biochemical recurrence-free survival (BCRFS) of 83.2% at a median of

**Table 3** Oncologic outcomes

Study	Year	Follow-up (months)	N	Prompt for biopsy	Number of patients biopsied	Biopsy results	Other oncologic outcomes analyzed	Other oncologic results	Patient metastases	Patient death
Kongnyuy <i>et al.</i> (13)	2017	36.6, median	163	PSA trigger	40.6% (Phoenix) and 35.7% (Stuttgart) had prostate biopsy	66.7% of positive follow-up biopsy had csPCa	BCRFS	3-year BCRFS: Phoenix—56%, Stuttgart—36%	NR	NR
Tay <i>et al.</i> (14)	2017	31, mean	166	NR	48 (28.9%)	2 (1.2%) positive	BCRFS	2- and 5-year BCRFS: Phoenix—80.7%/70%, Astro—82.1%/75%	NR	NR
Eishafei <i>et al.</i> (15)	2018	25.2, median	829	NR	228 (27.5%)	35.5% positive	BCRFS	83.20% (Phoenix) at median 22.8 months	NR	NR
Kongnyuy <i>et al.</i> (16)	2018	19, median	104	BCR	NR	NR	BCRFS	3-year BCRFS: Phoenix—62.5%	NR	NR
Werneburg <i>et al.</i> (17)	2018	NR	88	NR	NR	NR	NR	NR	NR	NR
Inoue <i>et al.</i> (18)	2019	6, median	5	NR	NR	NR	Median PSA decline rate, MRI lesional findings	Median PSA decline rate—71.4% at 6 months. MRI: 6–12 months—0 persistent lesions	NR	NR
Bakavicius <i>et al.</i> (19)	2019	11, median	126	NR	NR	NR	NR	NR	NR	NR
Shah <i>et al.</i> (20)	2019	27.8, median	122	PSA trigger	29 (23.8%) had “for cause” biopsies	20 had csPCa, 1 had GGG1, 8 benign. IFF—9, OFF—9, 3 had both	FFS, CSS, MFS, OS	At 3 years: FFS—90.5%, CSS—100%, MFS—98%, OS—96.1%	3 patients	4 died, none from cancer
Oishi <i>et al.</i> (21)	2019	40, median	160	Mandatory and PSA triggered	104 (65%)	At 3/5 years: APFS, 70%/47% CSPFS, 85%/63%	TFFS, RTFS, BCRFS, MFS, OS, CSS	At 5 years: TFFS—85%, RTFS—89%, BCRFS (Phoenix)—62%, MFS, OS, CSS—all 100%	2 patients	None
Wysock <i>et al.</i> (22)	2021	6, median	83	Mandatory	70 (84.3%)	7.1% of 6 months biopsy positive	PSA decrease at 6 months, MRI ability to predict IFF	Median decline in PSA—71%, MRI AUC—0.554 to predict IFF	NR	NR
Gregg <i>et al.</i> (23)	2021	74, median	23	Mandatory	21 of 23 (91.3%)	At 3 years—34.8% OFF	IFF and OFF	34.8% OFF at 3 years, 0 IFF at 74 months, 9 additional OFF	None	None

**Table 3** (continued)

Table 3 (continued)

Study	Year	Follow-up (months)	N	Prompt for biopsy	Number of patients biopsied	Biopsy results	Other oncologic outcomes analyzed	Other oncologic outcome results	Patient metastases	Patient death
Tan <i>et al.</i> (24)	2021	28, median	71	PSA trigger	42 (59%)	3 (7.1%) had csPca on target biopsy. Systematic biopsy: csPca 21.4% IFF 19%, OFF 2.4%	FFS, MFS, CSS	At 5 years: FFS—75%, MFS—100%, CSS—100%	None	None
Marra <i>et al.</i> (25)	2021	85, median	121	Mandatory and PSA triggered	115 (96.6%)	38.9% positive — GGG1 in 59.6%, GGG2 31.9%, GGG3 in 6.4%, GGG4 2.1%	TFFS, MFS, OS	At 5 and 10 years: TFFS—51.0%/40.2%. At 10 years: MFS—93.9%, OS—97.0%	5 patients	3 died, none from cancer

PSA, prostate specific antigen; csPca, clinically significant prostate cancer; BCRFS, biochemical recurrence-free survival; NR, not recorded; BCR, biochemical recurrence; FFS, failure-free survival; CSS, cancer specific survival; MRI, magnetic resonance imaging; MFS, metastasis-free survival; OS, overall survival; GGG, Gleason grade group; IFF, in-field failure; OFF, out-of-field failure; APFS, all prostate cancer-free survival; CSPFS, clinically significant prostate cancer-free survival; TFFS, treatment failure-free survival; RTFS, radical treatment-free survival; AUC, area under the curve.

22.8 months (15), two studies quoted 3-year BCRFS from 56–62.5% (13,16), and two articles described 5-year rates from 62–70% (14,21).

Nine (69.2%) studies reported follow-up biopsy data, with 23.8–96.6% of patients undergoing post-cryoablation biopsy. Reported findings were highly variable, including positive biopsy rates, in-field (IFF) *vs.* out-of-field (OFF) failure rates, and rates of finding csPca. Only four (30.8%) studies had a mandatory biopsy as part of a follow-up protocol, all with a varied approach. Oishi *et al.* (21) used systematic sextant biopsy with image-targeted sampling of suspicious areas at 12 months and described 5-year all Pca-free survival and csPca-free survival to be 47% and 63%, respectively. Wysock *et al.* (22) obtained four cores within the ablation zone and six systematic cores beyond the ablation zone at 6 months, finding 7.1% of their cohort were positive for Pca at 6-month biopsy. Gregg and colleagues implemented a 6-month 12 core biopsy template directed towards the medial and lateral aspects of sextant prostate regions and saw zero IFF and 34.8% OFF at 3 years (23). Marra *et al.* (25) performed a 12-month “standard control biopsy” without further specification and demonstrated a 38.9% positive biopsy rate, with 40.4% returning with  $\geq$  GGG2; 34.6% of recurrences were IFF, 25.3% were OFF, and 36% were both IFF and OFF.

Salvage therapy for treatment failure was reported in five studies (38.5%), with few studies distinguishing whether further treatment was for IFF or OFF. Marra *et al.* (25) mentioned 54 (44.6%) patients having salvage therapies, with 14.8% having redo focal cryoablation, 63% undergoing whole gland therapy such as radical prostatectomy (RP) or radiation, and 22.2% initiating androgen deprivation systemic therapy. Five- and 10-year radical treatment-free survival (RTFS) were 70.5% and 65%, respectively (25). In their study, Gregg *et al.* (23) commented on two patients requiring repeat cryoablation at three years for OFF, and two patients requiring treatment (1 radiation, 1 re-cryoablation) for further development of OFF at 74 months follow-up. Tan *et al.* (24) reported IFF in eight (19%) patients and OFF in one patient, with five overall recurrences treated with repeated partial cryoablation (four of which subsequently had nadir less than 1 ng/dL) and the rest undergoing either external beam radiotherapy (EBRT) or RP. In their cohort, Shah *et al.* (20) reported treatment failure-free survival to be 83.2%, with 21 cases (17.2%) of salvage: eight cases of repeat focal cryoablation, five RP, four radiation, and four cases of systematic therapy. Lastly, Oishi *et al.* (21) did not report specific salvage case numbers,

however they did present a 5-year RTFS of 89% in their cohort of 160 patients.

Only five (38.5%) studies commented on metastasis and overall survival (OS). Within these studies, 10 (2.0%) total patients developed metastases and seven (1.4%) patients died (none from PCa). When reported, metastasis-free survival (MFS), cancer-specific survival (CSS), and OS ranged from 93.9–100%, 100%, and 96.1–100%, respectively (20,21,23–25).

### **Functional outcomes and complications**

Table 4 presents data on complications and functional outcomes from the reviewed articles. In total, eight (61.5%) studies analyzed adverse events and seven reported on functional sequelae post-prostate focal cryoablation. Post-treatment urinary continence rates ranges were described as 95.1–100% by 3–12 months using definitions of EPIC score, “no leak”, or “no pad use”. Defined by various criteria, including IIEF score and more subjective measures such as “ability to penetrate”, potency rates following focal cryosurgery when presented ranged from 46.8–83.8%. Regarding notable complications, urinary retention rates were recorded at 0–9% post-focal cryoablation and recto-urethral fistula was seen in up to 0.8% of patients across all cohorts. Other reported possible adverse events included urinary tract infection (mentioned in three studies with a maximum rate of 9%) (19,20,25), hematuria (mentioned in one study with rate of 5%) (25), urethral sloughing (reported in one study with a rate of 3.2%) (19), penoscrotal edema (discussed in two articles with a maximum rate of 9.8%) (19,20), stricture (mentioned in one study with rate of 0.8%) (19), and osteomyelitis (mentioned in one study with rate of 0.8%) (20). In their comprehensive review of perioperative adverse events, Bakavicius *et al.* (19) further reported rare, isolated cases of dysuria, hematospermia, renal colic, pain, and an instance of an allergic reaction. Three articles reported stratified complications using the Clavien-Dindo criteria, reporting high-grade ( $\geq$  Clavien 3) in six patients (2.3%) out of a cumulative total of 266 across those studies (20,23,25).

### **Discussion**

First developed over 50 years ago, cryoablation employs the rapid freezing and thawing of intended target tissues currently using argon gas (12). Temperature lowering in the intended target to a minimum of  $-40$  °C promotes lethal

iceball formation resulting in denaturation of proteins and destruction of intracellular components, as well as extracellular ice crystal formation and a hyperosmotic extracellular environment that establishes a trans-cellular membrane concentration gradient (26). The resulting fluid shift into the intracellular space causes cells to distend and burst (26). This mechanism of prostate cell apoptosis is further augmented by deleterious effects to blood supply and the immune response related to iceball formation (26,27). Early initiatives implementing cryoablation into the PCa treatment paradigm focused on whole gland therapy, demonstrating adequate patient outcomes as well as a potential salvage therapy after radiation therapy failure (28,29). However, recent advances in imaging and diagnostics including mpMRI, fusion targeting, and 3-D mapping biopsy have supported the growth of focal therapy as an emerging alternative to whole gland PCa treatments in select cases (9).

Review of relevant articles from the past five years confirms the findings of our previous review that primary focal cryoablation for localized disease is well tolerated with overall minimal impact on urinary and sexual function (11). Complication rates mentioned in eight studies were all low, and high grade Clavien  $\geq 3$  complications did not surpass 4% in any study (20,23,25). Urinary retention was the most encountered adverse event and is likely related to reactive edema. Three studies mentioned time until catheter removal (range of 1–10 days), with two of these also reporting retention rates (19,22,23). Between those two studies, early post-cryotherapy retention occurred in 11 total patients, for a cumulative rate of 7.4% (19,23). Risk of retention can potentially be mitigated by increasing the time until postoperative trial of void; at Duke University, our protocol is maintenance of postoperative catheter for two weeks, obviating most of the early transient retention while providing sufficient time for the edema to resolve. With regards to continence, excellent rates were demonstrated in all reviewed studies, with six studies claiming 95.1–100% urinary control occurring as soon as 3 months post-treatment. However, all six articles utilized non-validated outcome measures including “no leak” or “no pad use” as clinical thresholds. One study did include assessment of urinary continence via Expanded Prostate Cancer Index Composite (EPIC) scores, quoting an initial reduction followed an improvement within 12 months (17). Sexual functional outcomes were also heterogeneously defined and reported. Notably, Tay *et al.*, Tan *et al.*, and Gregg *et al.* reported the lowest outcomes of all studies, quoting



**Table 4** Complications/functional outcomes

Study	Year	Complications	Definition of continence	Reported continence outcome	Definition of potency	Reported potency outcome
Kongnyuy <i>et al.</i> (13)	2017	NR	NR	NR	NR	NR
Tay <i>et al.</i> (14)	2017	Retention 6.6%, fistula 0%	No leak	95.1% at 12 months	Ability to have intercourse	46.8%
Elshafei <i>et al.</i> (15)	2018	NR	NR	NR	NR	NR
Kongnyuy <i>et al.</i> (16)	2018	NR	NR	NR	NR	NR
Werneburg <i>et al.</i> (17)	2018	NR	EPIC	Initial reduction then rises by 12 months	IIEF score	Lower early IIEF scores but rapid improvement by postoperative year 2
Inoue <i>et al.</i> (18)	2019	No perioperative complication observed	NR	NR	NR	NR
Bakavicius <i>et al.</i> (19)	2019	Retention 7.1%, UTI 3.2%, urethral sloughing (3.2%), penoscrotal edema (3.2%), penoscrotal hematoma (1.6%), perineal abscess (1.6%), hypotension (1.6%), fistula 0.8%, stricture 0.8%, dysuria (0.8%), hematospermia (0.8%), renal colic (0.8%), pain (0.8%), allergic reaction (0.8%), acute kidney injury (0%)	NR	NR	NR	NR
Shah <i>et al.</i> (20)	2019	Penoscrotal edema in 9.8%, UTI in 9%, retention in 4.1%, osteomyelitis in 0.8%, fistula 0%. Clavien 3 complications in 1.6%	No pad use	100% by 6 months	Ability to penetrate	83.8% still potent post-operation
Oishi <i>et al.</i> (21)	2019	No rectal fistula	No pad use	97%	3 or higher on IIEF question 2	73%
Wysock <i>et al.</i> (22)	2021	NR	NR	NR	NR	NR
Gregg <i>et al.</i> (23)	2021	2 (9%) grade 2 complications for retention, 1 patient (4%) had a Clavien 3 complication (placement of suprapubic catheter)	No pad use	100% by 6 months	IIEF score	Intercourse satisfaction decreased from median of 13 to 8.5 at 6 months
Tan <i>et al.</i> (24)	2021	No rectal fistula	No pad use	100% by 3 months	Ability to achieve an erection	58%
Marra <i>et al.</i> (25)	2021	Retention 8.3%, UTI 6.6%, hematuria 5%, fistula 0.8%, urethral stenosis 0.8%, urethral sloughing 0%, ≥ Clavien 3 complication in 3 patients (2.4%)	No pad use	96.00%	IIEF score	Median IIEF-5 14.5 (baseline 10)

NR, not recorded; EPIC, Expanded Prostate Cancer Index Composite; IIEF, International Index of Erectile Function; UTI, urinary tract infection.

post-treatment potency as 46.8%, 58%, and decreased International Index of Erectile Function (IIEF) score to 8.5 at 6 months, respectively (14,23,24). The heterogeneous ablation patterns of included cohorts prevent making any conclusions regarding association of more extensive ablation with lower postoperative sexual function. A potential meaningful clinical outcome for future studies incorporating validated patient-reported outcome measures (PROM) is a return to baseline function, considering preoperative functional scores (30). Other authors have also reported using stratified functional scores (mild, moderate, and severe categories) and considering “significant” changes in scores [3 point change in International Prostate Symptom Score (IPSS) score, and 4 point change in Sexual Health Inventory for Men (SHIM) score in 6 months] (31,32).

In 2015, the International Consensus of Urologic Disease (ICUD) convened an international expert panel to standardize outcome measures after focal therapy to provide consistency in reporting (33). Despite this, oncologic results from contemporary focal cryoablation reports often are confounded by heterogeneity with regards to preoperative risk stratification and lack of adherence to standard definitions of outcome measures for persistence, recurrence, and progression. In this review, at least two risk groups were included in nine of the 11 studies that offered preoperative biopsy pathology and 61.5% of cohorts included high risk patients, possibly contributing to the variation in certain results. Intuitively, different ablation patterns should have differing amounts of residual PSA-secreting prostate tissue remaining, making standardized biochemical definitions challenging (34). Failure after focal cryoablation can be divided into IFF and OFF, with the former signifying inadequate treatment and the latter signifying a “selection failure”, especially if identified within the first 12–18 months (35). Management can be additionally stratified based on degree of disease, as some authors further define IFF as significant volume ( $\geq 0.2$  cc or  $\geq 7$  mm diameter) of GGG2 within the treated area based on pathological data from the International Society of Urologic Pathology (ISUP) (36). Additionally, GGG1 tumors can generally be surveilled without immediate intervention (35). While some have suggested mandatory biopsy within 12 months to assess efficacy of the procedure, only 4 of 13 included studies featured mandatory re-biopsy, with most implementing a “for cause” biopsy based on a PSA trigger in consideration of biochemical recurrence (BCR) (37). BCR definitions also varied, with Phoenix (5 studies), Stuttgart (1 study), and Astro criteria (1 study) all

represented. One study commented on the possible role of mpMRI to monitor these patients but featured a poor AUC of only 0.554 to predict IFF based on mpMRIs beginning at 6 months postoperatively (22); the finding reaffirms that mpMRI alone is insufficient to detect recurrence and periodic histologic sampling is still necessary (36).

Looking beyond initial treatment, further debate has centered on management options once suspicion for failure or BCR is confirmed with biopsy-proven recurrence. For csPCa identified as IFF, options include repeat targeted ablative treatment with the same or different energy, or whole gland approaches such as total ablation, RP, or radiotherapy (35,38). On the other hand, OFF may be *de novo* lesions or disease missed at initial evaluation due to issue with sampling or invisibility on mpMRI (35). While these latter patients can be candidates for further targeted ablation, challenges of targeting MRI-invisible lesions may shift these patients towards whole gland management strategies (35). Further controversy exists regarding whether repeat focal therapy offers acceptable oncologic outcome compared to whole gland approaches however, this is likely due to patient selection factors (39). One advantage of ablative techniques is the ability to repeat the procedure in cases of treatment failure (35). One of the studies included in this review allowed for up to one further session of cryotherapy as part of the initial focal therapy intervention (20), with four other studies reporting use of repeated focal ablative intervention for treatment failure (21,23–25). Regarding more aggressive whole gland salvage approaches, one recent study quoted progression-free survival after salvage RP and radiation post-focal therapy failure to be 80.4% and 100% at 3 years, respectively (40). Another study of 82 patients undergoing RP after FT failure demonstrated only a 36% progression-free survival at 3 years but did describe a 12-month continence rate of 83% and minimal perioperative comorbidity (41). In general, the current level of evidence regarding management for FT failure is low and limited to retrospective series (38).

PCa oncologic outcomes are ideally evaluated at least 10–15 years after treatment due to the long natural history of the disease (11). Both the treated and untreated areas need to be continually assessed radiographically and histologically. As focal cryoablation is still considered a developing technique, few cohorts have matured enough to provide such long-term outcomes (36). Nonetheless, reviewed studies providing oncologic results did highlight a 2% cumulative rate of patients developing metastases. While the overall review cohort featured mean/median follow-

up of 6–85 months, two of the included papers featured longer term follow-up of 74 (23) and 85 months (25), with both examining treatment failure rates. Both studies featured high compliance with mandatory post-procedural biopsy and reported similar outcomes. Gregg *et al.* (23) reported no IFF and 34.8% OFF at three years with no IFF and nine subsequent OFF at 74 months (all GGG1). With even longer follow-up at 85 months, Marra *et al.* (25) reported a 38.9% positive biopsy rate and a 10-year treatment failure-free survival of 40.2%. For reference, the longest follow-up reported in our prior review in 2016 was that of Lian *et al.* (42) (63 months), in which those authors presented 41 patients with 7 (17.1%) positive biopsies (2 IFF and 5 OFF, all GGG2) (38). Increasing to the ideal level of follow-up will allow focal cryotherapy cohorts to adequately assess key oncologic outcomes such as CSS and OS. These outcomes have been previously reported with whole gland cryoablation, with one example study demonstrating 87% CSS and 56.6% OS at 10 years in mostly high-risk patients (43).

The current review features studies with highly-varied approaches to biopsy strategy for patient selection, including only three cohorts incorporating 3-D template mapping biopsies and one utilizing a confirmatory systematic biopsy (19,20,23,24). Indeed, such a heterogeneous approach is also evidenced in the literature, including usage of conventional systematic biopsy, saturation biopsy, fusion targeted biopsy, and 3-D template mapping biopsy. As such, there is a need to optimize and standardize how patients are selected for focal cryotherapy. Prior research has demonstrated that extended systematic biopsy compared to the classic sextant format improves diagnostic accuracy from 49% to 59% and improves detection of unilateral PCa (44). Various innovative approaches have also been investigated with regards to mpMRI-targeted biopsy. Aminsharifi *et al.* (45) previously demonstrated the utility of employing targeted biopsy with only a sextant systematic biopsy as a method of reducing overall number of biopsy cores through limiting random systematic biopsy cores, with any cancer and csPCa detected at 74.4% and 39.5%, respectively, in active surveillance patients. Furthering the investigation into targeted biopsy technique, Tracy *et al.* (46) demonstrated incremental benefit in the utilization of an increased number of targeted biopsy cores, with 52% detection of csPCa at fifth lesional biopsy core compared to 26% for the first biopsy core. While laborious and requiring anesthesia, 3-D template mapping biopsy with 5 mm sampling offers perhaps the most precise 3-D representation of the

location, volume and extent of disease, corresponding with a high rate of upgrading of disease after a previous TRUS biopsy to as high as 46% (9,47,48). Performed in a similar lithotomy position to transperineal approaches to focal therapy, this 3-D biopsy platform offers a fixed set of reproducible coordinates that translates well from biopsy to cryoablation (48).

Patient selection for focal cryoablation has and will also continue to be aided by developments with prostate imaging (49). US, universally used in a transrectal fashion for real-time imaging when performing cryoablation, has seen several recent developments. Contrast-enhanced US, better suited to detect regions of increased vascularity, was demonstrated to have improved cancer detection rates of 75% on targeted biopsy *vs.* 48.2% with standard transrectal US (50). Further combined with real-time elastography, contrast-enhanced US has demonstrated 89.7% cancer detection on targeted biopsy. mpMRI has had an ever-increasing role due to the ability to identify potential lesions, facilitate targeted biopsy and monitor treatment changes post-procedure. Currently performed at 1.5 or 3 Tesla, there have been investigations into the potential utility of an ultra-high magnetic field strength of 7 Tesla. Vos *et al.* (51) demonstrated satisfactory-to-good overall image quality on T2-weighted imaging at 7 Tesla without an endorectal coil and the ability to identify csPCa lesions in patients with biopsy-proven lesions in the peripheral and transition zones. The authors surmised that increased spatial resolution with 7 Tesla MRI may enable new functional imaging techniques such as spectroscopic imaging of low-concentration metabolites (51). The utility of prostate specific membrane antigen positron emission tomography (PSMA-PET) to identify and locate tumor foci within the prostate has also been recently investigated, showing a slightly higher specificity (95% *vs.* 94%) and positive predictive value (85% *vs.* 81%) compared to mpMRI to identify tumor foci on whole-mount histopathology (52). Nonetheless, the authors stated neither PSMA-PET nor mpMRI can currently replace prostate biopsy as a significant proportion of cancers are potentially underestimated and missed by both imaging modalities (52).

This review of contemporary primary focal cryoablation studies over the last five years demonstrates the tolerability and efficacy of the procedure to minimize detrimental functional outcomes in these patients. Recent advances in the field have resulted in efforts to expand indications for focal cryoablation. Evidenced by the high proportion of intermediate and high risk patients featured by studies

included in this review, focal cryoablation is increasingly being investigated as an alternative treatment for higher risk disease. Further comparative research is required to assess the potential role of focal cryoablation to adequately eradicate higher-risk tumor cell clones (34). Focal cryoablation has also been preliminarily examined as a salvage treatment option post radiotherapy, with early reports demonstrating encouraging potency rates and similar 2-year oncologic outcomes compared to salvage total cryoablation (53). At this time, such endeavors should be considered developmental due to the lack of consistent long-term and high quality data.

## Conclusions

Focal cryoablation in recent years has continued to demonstrate promising functional outcomes and adequate short-to-intermediate term oncologic outcomes. The current level of available data is primarily low and retrospective in nature, highlighting the need for further investigations. Research is needed to elucidate the optimal means to monitor these patients post-procedure and consider the best salvage option in cases of failure. With furthering of technologic advancements and research efforts, it is reasonable to expect continued improvement of patient selection and outcomes, as well as for the sustained expansion of potential indications.

## Acknowledgments

*Funding:* None.

## Footnote

*Reporting Checklist:* The authors have completed the Narrative Review reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5033/rc>

*Conflicts of Interest:* Both authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-5033/coif>). TJP is serving as the President of Focal Therapy Society with no remuneration. The other author has no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Buyyounouski MK, Choyke PL, McKenney JK, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017;67:245-53.
2. Koch MO, Gardner TA. Thermal-based treatment options for localized prostate cancer. *Curr Treat Options Oncol* 2005;6:379-87.
3. Beerlage HP. Alternative therapies for localized prostate cancer. *Curr Urol Rep* 2003;4:216-20.
4. Begg CB, Riedel ER, Bach PB, et al. Variations in morbidity after radical prostatectomy. *N Engl J Med* 2002;346:1138-44.
5. Benoit RM, Naslund MJ, Cohen JK. Complications after prostate brachytherapy in the Medicare population. *Urology* 2000;55:91-6.
6. Cao C, Chandrakumar D, Gupta S, et al. Could less be more?—A systematic review and meta-analysis of sublobar resections versus lobectomy for non-small cell lung cancer according to patient selection. *Lung Cancer* 2015;89:121-32.
7. Pierorazio PM, Johnson MH, Patel HD, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. *J Urol* 2016;196:989-99.
8. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. *N Engl J Med* 2002;347:1227-32.
9. Barqawi AB, Stoimenova D, Krughoff K, et al. Targeted focal therapy for the management of organ confined prostate cancer. *J Urol* 2014;192:749-53.
10. Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 2012;367:203-13.

11. Tay KJ, Polascik TJ. Focal Cryotherapy for Localized Prostate Cancer. *Arch Esp Urol* 2016;69:317-26.
12. Babaian RJ, Donnelly B, Bahn D, et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. *J Urol* 2008;180:1993-2004.
13. Kongnyuy M, Lipsky MJ, Islam S, et al. Predictors of biochemical recurrence after primary focal cryosurgery (hemiblation) for localized prostate cancer: A multi-institutional analytic comparison of Phoenix and Stuttgart criteria. *Urol Oncol* 2017;35:530.e15-9.
14. Tay KJ, Polascik TJ, Elshafei A, et al. Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. *J Endourol* 2017;31:564-71.
15. Elshafei A, Tay KJ, Kara O, et al. Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. *Clin Genitourin Cancer* 2018;16:e477-82.
16. Kongnyuy M, Islam S, Mbah AK, et al. PSA kinetics following primary focal cryotherapy (hemiblation) in organ-confined prostate cancer patients. *World J Urol* 2018;36:209-13.
17. Werneburg GT, Kongnyuy M, Halpern DM, et al. Effects of Focal vs Total Cryotherapy and Minimum Tumor Temperature on Patient-reported Quality of Life Compared With Active Surveillance in Patients With Prostate Cancer. *Urology* 2018;113:110-8.
18. Inoue Y, Ushijima S, Shiraishi T, et al. Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer. *Int J Urol* 2019;26:317-9.
19. Bakavicius A, Sanchez-Salas R, Muttin F, et al. Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology. *J Endourol* 2019;33:509-15.
20. Shah TT, Peters M, Eldred-Evans D, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. *Eur Urol* 2019;76:98-105.
21. Oishi M, Gill IS, Tafuri A, et al. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years. *J Urol* 2019;202:1188-98.
22. Wysock JS, Becher E, Gogaj R, et al. Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. *Prostate Cancer Prostatic Dis* 2021;24:114-9.
23. Gregg JR, Borregales LD, Choi H, et al. Prospective trial of regional (hockey-stick) prostate cryoablation: oncologic and quality of life outcomes. *World J Urol* 2021;39:3259-64.
24. Tan WP, Chang A, Sze C, et al. Oncological and Functional Outcomes of Patients Undergoing Individualized Partial Gland Cryoablation of the Prostate: A Single-Institution Experience. *J Endourol* 2021;35:1290-9.
25. Marra G, Soeterik T, Oreggia D, et al. Long-term Outcomes of Focal Cryotherapy for Low- to Intermediate-risk Prostate Cancer: Results and Matched Pair Analysis with Active Surveillance. *Eur Urol Focus* 2022;8:701-9.
26. Habibian DJ, Katz AE. Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer. *Int J Hyperthermia* 2016;32:795-800.
27. Baust JG, Gage AA, Bjerklund Johansen TE, et al. Mechanisms of cryoablation: clinical consequences on malignant tumors. *Cryobiology* 2014;68:1-11.
28. Polascik TJ, Mayes JM, Mouraviev V. From whole-gland to targeted cryoablation for the treatment of unilateral or focal prostate cancer. *Oncology (Williston Park)* 2008;22:900-6; discussion 906-7, 914.
29. Kimura M, Mouraviev V, Tsivian M, et al. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. *BJU Int* 2010;105:191-201.
30. Shah TT, Peters M, Miah S, et al. Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer. *Eur Urol Focus* 2021;7:301-8.
31. Rosen RC, Allen KR, Ni X, et al. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. *Eur Urol* 2011;60:1010-6.
32. Barry MJ, Cantor A, Roehrborn CG, et al. Relationships among participant international prostate symptom score, benign prostatic hyperplasia impact index changes and global ratings of change in a trial of phytotherapy in men with lower urinary tract symptoms. *J Urol* 2013;189:987-92.
33. Polascik TJ, Tay KJ, Ghai S, et al. Surveillance after prostate focal therapy. In: Sanchez-Salas S, Desai M. editors. *Image-guided therapies for Prostate and Kidney Cancer*. Montréal: Société Internationale d'Urologie (SIU), 2016.
34. van der Poel HG, van den Bergh RCN, Briers E, et al.

- Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. *Eur Urol* 2018;74:84-91.
35. Lebastchi AH, George AK, Polascik TJ, et al. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus. *Eur Urol* 2020;78:371-8.
  36. Tay KJ, Amin MB, Ghai S, et al. Surveillance after prostate focal therapy. *World J Urol* 2019;37:397-407.
  37. Scheltema MJ, Tay KJ, Postema AW, et al. Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. *World J Urol* 2017;35:695-701.
  38. Marra G, Valerio M, Emberton M, et al. Salvage Local Treatments After Focal Therapy for Prostate Cancer. *Eur Urol Oncol* 2019;2:526-38.
  39. Mustafa M, Delacroix S, Ward JF, et al. The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. *World J Surg Oncol* 2015;13:340.
  40. von Hardenberg J, Cash H, Koch D, et al. Triggers and oncologic outcome of salvage radical prostatectomy, salvage radiotherapy and active surveillance after focal therapy of prostate cancer. *World J Urol* 2021;39:3747-54.
  41. Marconi L, Stonier T, Tourinho-Barbosa R, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. *Eur Urol* 2019;76:27-30.
  42. Lian H, Zhuang J, Yang R, et al. Focal cryoablation for unilateral low-intermediate-risk prostate cancer: 63-month mean follow-up results of 41 patients. *Int Urol Nephrol* 2016;48:85-90.
  43. Cheetham P, Truesdale M, Chaudhury S, et al. Long-term cancer-specific and overall survival for men followed more than 10 years after primary and salvage cryoablation of the prostate. *J Endourol* 2010;24:1123-9.
  44. Tsivian M, Kimura M, Sun L, et al. Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. *BJU Int* 2010;105:1089-92.
  45. Aminsharifi A, Gupta RT, Tsivian E, et al. Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy. *Eur J Radiol* 2019;110:7-13.
  46. Tracy CR, Flynn KJ, Sjoberg DD, et al. Optimizing MRI-targeted prostate biopsy: the diagnostic benefit of additional targeted biopsy cores. *Urol Oncol* 2021;39:193.e1-6.
  47. Barqawi AB, Rove KO, Gholizadeh S, et al. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. *J Urol* 2011;186:80-5.
  48. Kanthabalan A, Emberton M, Ahmed HU. Biopsy strategies for selecting patients for focal therapy for prostate cancer. *Curr Opin Urol* 2014;24:209-17.
  49. Ashrafi AN, Tafuri A, Cacciamani GE, et al. Focal therapy for prostate cancer: concepts and future directions. *Curr Opin Urol* 2018;28:536-43.
  50. Zhao HX, Xia CX, Yin HX, et al. The value and limitations of contrast-enhanced transrectal ultrasonography for the detection of prostate cancer. *Eur J Radiol* 2013;82:e641-7.
  51. Vos EK, Lagemaat MW, Barentsz JO, et al. Image quality and cancer visibility of T2-weighted magnetic resonance imaging of the prostate at 7 Tesla. *Eur Radiol* 2014;24:1950-8.
  52. Rhee H, Thomas P, Shepherd B, et al. Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. *J Urol* 2016;196:1261-7.
  53. Tan WP, ElShafei A, Aminsharifi A, et al. Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer. *Clin Genitourin Cancer* 2020;18:e260-5.

**Cite this article as:** Kotamarti S, Polascik TJ. Focal cryotherapy for prostate cancer: a contemporary literature review. *Ann Transl Med* 2023;11(1):26. doi: 10.21037/atm-21-5033